-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Yuandong Biotech (688513.SH) announced that the company's self-developed 2 improved new drug aminophen oxycodone sustained-release tablets have passed medical insurance negotiations and were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” for the first time. This drug is used to treat moderate to severe pain after surgery. It should be used when patients cannot tolerate alternative treatment (such as non-opioid drugs) or where alternative treatment does not meet analgesia needs and requires treatment with opioids.
Share
Listen to the news
Zhitong Finance App News, Yuandong Biotech (688513.SH) announced that the company's self-developed 2 improved new drug aminophen oxycodone sustained-release tablets have passed medical insurance negotiations and were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” for the first time. This drug is used to treat moderate to severe pain after surgery. It should be used when patients cannot tolerate alternative treatment (such as non-opioid drugs) or where alternative treatment does not meet analgesia needs and requires treatment with opioids.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending